<!DOCTYPE html>
<html>
	<head>
		<link rel="stylesheet" href="main.css">
		<title>ME/CFS Research</title>
		<!-- favicon -->
		<link rel="apple-touch-icon" sizes="180x180" href="/apple-touch-icon.png">
		<link rel="icon" type="image/png" sizes="32x32" href="/favicon-32x32.png">
		<link rel="icon" type="image/png" sizes="16x16" href="/favicon-16x16.png">
		<link rel="manifest" href="/site.webmanifest">
	</head>
	<body>
		<div class="main">
			<h1><a href="/">ME/CFS Research</a> :: Antivirals</h1>
			<hr class="styled top">
			<div class="main-column">
				<h2>Antiviral Pharmacokinetic Information</h2>
				<p class="passage">
					The following information on antivirals might be useful.
				</p>

<h4><u>Epstein-Barr Virus</u></h4>
<ul>

	<li>
		<span style="font-style:italic;font-weight:bold">acyclovir</span> (metabolite of valacyclovir/Valtrex)
		<ul>
			<li>EBV IC50: median 7.0μM (1.58μg/mL*), max: 10μM (2.25μg/mL*)
				<ul>
					<li> 4.1 μM (<a href="https://doi.org/10.1128/jvi.02487-09">Meng 2010</a>)</li>
					<li> 6.0 μM (<a href="https://doi.org/10.1128/jvi.34.2.560-568.1980">Colby 1980</a>)</li>
					<li> 8.6 μM (<a href="https://doi.org/10.1073/pnas.2002392117">Drosu 2020</a>)</li>
					<li>10.0 μM (<a href="https://doi.org/10.1128/jvi.73.9.7271-7277.1999">Zacny 1999</a>)</li>
				</ul>
			<li>Pharmacokinetics of 1,000mg valacyclovir<br>
				<ul>
					<li>Acyclovir Cmax: 5.65 μg/mL ± 2.37 (when given once daily) or 4.96 μg/mL ± 0.64 (when given 4x/day)</li>
					<li>Cmax is 220% of the IC50max for EBV</li>
					<li>Elimination half-life: 2.91 hr ± 0.63 (young) or 3.11 ± 0.51 (elderly) (healthy volunteers with normal renal function)</li>
					<li>est. 1g 4x daily Cavg = Cmax*0.53† = 2.63 μg/mL; this is 116.8% of the IC50max</li>
					<li>est. 1g 4x daily Cmin = Cmax*0.24† = 1.19 μg/mL; this is 52.8% of the IC50max</li>
				</ul>
			</li>
			<li>*μM to μg/mL conversion factor: 4.44 μM = 1 μg/mL (source: ChatGPT and <a href="https://doi.org/10.1186/1746-6148-2-13">Van der Meulen 2006</a>)</li>
			<li>†Indicates AI assisted calculation</li>
		</ul>
	</li>

	<li style="margin-top:1em">
		<span style="font-style:italic;font-weight:bold">ganciclovir</span> (metabolite of valganciclovir/Valcyte)
		<ul>
			<li>EBV IC50: median 0.78μM (0.20μg/mL*), max 1.50μM (0.38μg/mL*)
				<ul>
					<li>0.05μM (Lin 1983)</li>
					<li>1.50μM (<a href="https://doi.org/10.1128/jvi.02487-09">Meng 2010</a>)</li>
					<li>0.65μM (Drosu 2020)</li>
				</ul>
			</li>
			<li>Pharmacokinetics of 900mg valganciclovir once daily with food: (ref. Package insert)<br>
				<ul>
					<li>Ganciclovir Cmax: 5.61 μg/mL ± 1.52</li>
					<li>Cmax is 1475% of the IC50max for EBV</li>
					<li>Elimination half-life: 4.08 hr ± 0.76</li>
					<li>est. Cavg = Cmax*0.240† = 1.35 μg/mL; this is 355% of the IC50max</li>
					<li>est. Cmin = Cmax*0.016† = 0.09 μg/mL; this is 6% of the IC50max</li>
				</ul>
			</li>
			<li>Compared to acyclovir, the viral inhibitory effect persists longer after drug removal (Lin 1983)</li>
			<li>Ganciclovir is associated with liver toxicity and liver cancer which limits the dosage and treatment duration</li>
			<li>*μM to μg/mL conversion factor: 3.99 μM = 1 μg/mL (source: Package insert)</li>
			<li>†Indicates AI assisted calculation</li>
		</ul>
	</li>

	<li style="margin-top:1em">
		<span style="font-style:italic;font-weight:bold">tenofovir alafenamide</span> (Vemlidy)
		<ul>
			<li>EBV IC50: 0.084μM (0.040 μg/mL, ChatGPT conversion) (Drosu 2020)</li>
			<li>Cmax = 0.27μg/mL</li>
			<li>Cmax is 675% of the IC50 for EBV</li>
			<li>Compared to acyclovir, the viral inhibitory effect persists longer after drug removal (Drosu 2020)</li>
		</ul>
	</li>
</ul>

			</div>
			<hr class="styled bottom">
			<p class="footer"><a href="https://github.com/mecfsresearch/mecfsresearch.github.io">Contribute or Submit Feedback</a></p>
		</div>
	</body>
</html>
